A
A
Home

Latest news

argenx Announces Positive Topline Phase 3 ADAPT Trial Results

argenx today announced positive topline data from the pivotal ADAPT trial of efgartigimod.

ADAPT met its primary endpoint defined as percentage of responders on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score among acetylcholine receptor-antibody positive (AChR-Ab+) generalized...

Read more

Reaching Patients Through
Immunology Innovation

The science of co-creation drives our quest to engineer life-changing immunology solutions, the resilient spirit of patients fuels our urgency to deliver them.

The infinity sign symbolizes our commitment to science and patients; it has no bounds.

Infinity argenx

Patients

argenx infinity

Innovation

 
 
 

Where we operate

Our innovation

Together We Discover

We know that leaps in progress will come from collaboration and incorporating innovation into every step. We embrace the power of the collective – together we are better.

Innovation

Our Discoveries

At argenx, we’ve created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate the discovery of novel targets, disease pathways and differentiated therapeutic antibodies.

 

Eri, MG Patient, Fights Against the Odds

Eri

We Hear You

"When I was younger they told me I would never walk again, but I grew up playing basketball, running... read more

Patient story
Lisa Ann, PV Patient, Motorcyle Enthusiast

Lisa Ann

We Hear You

"I woke up and both of my eyes were swollen shut. The doctor thought I was having a really bad... read more

Patient story

Doing the Unthinkable

argenx comes from the story of the Argonauts – we want to achieve the unthinkable together.

Dare To Do More

We dare you to see where argenx can take your career next.

List of jobs

Pipeline

Product Candidates

Our proprietary portfolio is focused on first-in-class product candidates engineered in collaboration with our academic partners to help translate immunology breakthroughs into medicines.

Our Pride

Efgartigimod

Target:
FcRn

We are investigating efgartigimod for the treatment of myasthenia gravis and other severe autoimmune diseases.

Designed to block FcRn and reduce IgGs, efgartigimod could be a rational approach to treating diseases where IgG antibodies are pathogenic or disease-causing.

 

 
Phase 3

Cusatuzumab

Target:
CD70

Janssen logo

We have a global collaboration and licensing agreement with Janssen R&D to develop and commercialize cusatuzumab for the treatment of hematological malignancies.

Cusatuzumab is designed with multiple mechanisms of action to kill malignant cells such as leukemia blasts and stem cells.

 

 
Phase 2